NGF and peripheral neuropathy: Furthermore, these findings demonstrate the clinical relevance of developing an antibody-based novel analgesic to inhibit NGF-mediated nociceptor signalling, to treat the painful symptoms of chemotherapy induced peripheral neuropathy in childhood survivors of cancer.